$0.38 Earnings Per Share Expected for Bruker Co. (NASDAQ:BRKR) This Quarter

Equities research analysts predict that Bruker Co. (NASDAQ:BRKR) will announce $0.38 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Bruker’s earnings, with the highest EPS estimate coming in at $0.39 and the lowest estimate coming in at $0.37. Bruker posted earnings per share of $0.37 in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 7th.

According to Zacks, analysts expect that Bruker will report full year earnings of $1.61 per share for the current year, with EPS estimates ranging from $1.58 to $1.63. For the next year, analysts forecast that the business will post earnings of $1.84 per share, with EPS estimates ranging from $1.80 to $1.88. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Bruker.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, August 1st. The medical research company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The business had revenue of $490.20 million for the quarter, compared to the consensus estimate of $477.70 million. Bruker had a return on equity of 27.10% and a net margin of 9.57%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.25 EPS.



Several research firms have weighed in on BRKR. Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and boosted their price target for the company from $32.00 to $48.00 in a research note on Monday, July 15th. BTIG Research upped their target price on Bruker to $57.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Barclays restated a “hold” rating and issued a $44.00 target price on shares of Bruker in a research note on Monday, June 24th. Needham & Company LLC set a $57.00 target price on Bruker and gave the stock a “strong-buy” rating in a research note on Monday, June 24th. Finally, ValuEngine upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, August 31st. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $49.80.

Bruker stock traded down $0.42 during trading hours on Thursday, hitting $42.50. 409,244 shares of the stock traded hands, compared to its average volume of 787,845. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.19 and a quick ratio of 1.27. The firm’s 50 day moving average price is $42.25 and its 200-day moving average price is $42.87. The stock has a market capitalization of $6.73 billion, a price-to-earnings ratio of 30.36, a P/E/G ratio of 2.17 and a beta of 1.41. Bruker has a 1 year low of $26.10 and a 1 year high of $51.41.

The business also recently announced a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Tuesday, September 3rd were paid a $0.04 dividend. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.38%. Bruker’s payout ratio is 11.43%.

In other news, VP Mark Munch sold 47,203 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $42.87, for a total value of $2,023,592.61. Following the sale, the vice president now owns 96,063 shares in the company, valued at $4,118,220.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Burkhard Prause sold 15,702 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $42.96, for a total value of $674,557.92. Following the completion of the transaction, the chief executive officer now directly owns 1,338 shares of the company’s stock, valued at approximately $57,480.48. The disclosure for this sale can be found here. 26.50% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its holdings in shares of Bruker by 4.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,013,763 shares of the medical research company’s stock valued at $30,178,000 after acquiring an additional 46,244 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Bruker during the first quarter worth about $2,873,000. State Board of Administration of Florida Retirement System raised its stake in Bruker by 4.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 150,679 shares of the medical research company’s stock worth $5,792,000 after acquiring an additional 5,877 shares during the period. California Public Employees Retirement System raised its stake in Bruker by 25.9% during the first quarter. California Public Employees Retirement System now owns 268,050 shares of the medical research company’s stock worth $10,304,000 after acquiring an additional 55,189 shares during the period. Finally, CIBC Asset Management Inc acquired a new stake in Bruker during the first quarter worth about $214,000. 66.59% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Recommended Story: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.